AccuRNA

AccuRNA is a Japanese biotechnology company dedicated to the development of innovative mRNA therapeutics using a proprietary drug delivery system. Spun out from the University of Tokyo, the company utilizes a unique polyplex nanomicelle technology designed to overcome the inherent stability and delivery challenges of mRNA. This platform enables the protection of mRNA from enzymatic degradation and ensures efficient delivery to target tissues, such as joints and the central nervous system. AccuRNA's current pipeline focuses on regenerative medicine, with lead programs targeting osteoarthritis and spinal cord injury. By leveraging its advanced delivery capabilities, the company aims to expand the therapeutic application of mRNA beyond vaccines into treatments for chronic and intractable diseases.